雷尼替丁和硫糖铝作为胃溃疡疾病的维持治疗：内镜控制及瘢痕评估
Ranitidine and sucralfate as maintenance therapy for gastric ulcer disease: endoscopic control and assessment of scarring.
作者信息
Takemoto T, Namiki M, Ishikawa M, Tsuneoka K, Oshiba S, Kawai K, Ogawa N
机构信息
Yamaguchi University School of Medicine, Asahikawa Medical College, Japan.
出版信息
Gut. 1989 Dec;30(12):1692-7. doi: 10.1136/gut.30.12.1692.
The efficacy of ranitidine (150 mg nocte), and sucralfate (1 g tds) as maintenance therapy to prevent gastric ulcer relapse was evaluated in a 12 month trial in 363 patients. The relapse rates were 8.8% at three months, 14.7% at six months, 18.1% at nine months, and 21.0% at 12 months for the ranitidine group and 14.7%, 21.3%, 29.9%, and 30.2% respectively for the sucralfate group. At nine and 12 months the cumulative relapse rates for the ranitidine group were significantly lower than those for the sucralfate group (p less than 0.05). In both groups ulcers recurred mainly from red scars observed at the endoscopic scarring stage. This indicated the necessity of drug treatment up to the white scar stage. The results suggest that ranitidine is effective in preventing gastric ulcer relapse.
在一项针对363例患者的为期12个月的试验中，评估了雷尼替丁（150毫克，每晚一次）和硫糖铝（1克，每日三次）作为预防胃溃疡复发的维持疗法的疗效。雷尼替丁组在3个月时的复发率为8.8%，6个月时为14.7%，9个月时为18.1%，12个月时为21.0%；硫糖铝组的复发率分别为14.7%、21.3%、29.9%和30.2%。在9个月和12个月时，雷尼替丁组的累积复发率显著低于硫糖铝组（p小于0.05）。在两组中，溃疡主要从内镜下瘢痕形成阶段观察到的红色瘢痕复发。这表明在白色瘢痕阶段之前进行药物治疗的必要性。结果表明雷尼替丁在预防胃溃疡复发方面是有效的。
Zotero 插件